FDA rejects Amgen’s focus for Xgeva

<p>(Reuters) – U.S. health regulators deserted a <span>application</span> by <span>Amgen Inc</span>, a world’s biggest <span>biotechnology company</span>, to enhance a use of a drug <span>Xgeva</span> to check a widespread of tumors to a bone in patients pang from modernized <span>prostate cancer</span>.</p>
<p> Xgeva and a associated osteoporosis drug Prolia are seen as among a many critical expansion drivers for Amgen and might assistance equivalent disappearing sales of anemia drugs, analysts say.</p>
<p> The <span>Food and Drug Administration</span> (FDA) has dynamic that a risks transcend a outcome of a due focus and has asked for information from adequate and well-controlled trials, Amgen said.</p>
<p> Xgeva is already authorized to forestall fractures in patients with modernized prostate cancer that has migrated to a bone. Amgen...